Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers

• Published in: Clinical therapeutics Vol. 32; no. 1; pp. 146 - 160
• Main Authors: Vaughan, David, PhD, Speed, Joanne, BSc, Medve, Robert, MD, Andrews, John S., PhD
• Format: Journal Article
• Language: English
• Published: Bridgewater, NJ EM Inc USA 2010; Elsevier; Elsevier Limited
• Subjects: 5-HT 1B/D agonist; Administration, Oral; Adolescent; Adult; Area Under Curve; Biological and medical sciences; Chromatography, High Pressure Liquid - methods; Dipeptidyl Peptidase 4 - blood; Double-Blind Method; dual-action; Female; Humans; Internal Medicine; Male; Medical Education; Medical sciences; Middle Aged; Nitric Oxide Synthase - antagonists & inhibitors; NOS inhibitor; NXN-188; pharmacokinetics; Pharmacology. Drug treatments; Serotonin Receptor Agonists - administration & dosage; Serotonin Receptor Agonists - pharmacokinetics; Tandem Mass Spectrometry - methods; Young Adult; pharmacokinetics; NXN-188; dual-action; NOS inhibitor; 5-HT 1B/D agonist; Human; Agonist; Healthy subject; Nitric oxide synthase inhibitor; Toxicity; Single dose; Enzyme inhibitor; Multiple dose; Randomization; Double blind study; Safety; Pharmacokinetics; 5-HT
• ISSN: 0149-2918; 1879-114X
• DOI: 10.1016/j.clinthera.2010.01.006

Abstract Background : NXN-188 is a dual-action oral therapeutic being developed for the treatment of acute migraine. The mechanism of action of NXN-188 involves inhibition of both the neuronal nitric oxide synthase enzyme isoform and affinity for serotonin (5-hydroxytryptamine1B/D) receptors. Objectives : The aims of the initial Phase I clinical studies were to compare the pharmacokinetic (PK) properties of NXN-188 administered as a single dose or multiple twice-daily doses to healthy adult volunteers and to determine the tolerability of NXN-188 in these individuals. Methods : Healthy adult male and female subjects were enrolled in 5 Phase I, randomized, double-blind studies, all of which (except for a fed/fasted trial) were placebo controlled. In the 4 single-dose studies, which differed with respect to feeding status and the formulation used (capsules or solution), subjects received NXN-188 at doses of 2 to 800 mg (0.027-11.2 mg/kg). In the repeat-dose study, subjects received 50-mg (0.71 mg/kg) doses twice daily for 4 days. Serum samples were analyzed for NXN-188 using validated HPLC-MS/MS methods. Standard clinical laboratory analyses (chemistry, hematology, and urinalysis) and measurements of serum creatine kinase and myoglobin levels were conducted at screening, admission, discharge, and follow-up. Baseline and postexposure values were compared to assess tolerability. Electrocardiography and physical examination were conducted at screening and at discharge and follow-up if any negative change occurred from the previous findings. Vital signs (heart rate, blood pressure, respiration), including assessment for orthostatic changes, were measured at screening, check-in, and follow-up visits (⪯1 hour before dosing, every 30 minutes for the first 4 hours, then every hour for the next 4 hours, then every 4 hours for the remainder of the 24-hour study). Adverse events were recorded, reviewed, and monitored throughout the study. Results : Two hundred three subjects (102 women, 101 men) 18 to 50 years of age were enrolled in the 5 studies; 168 subjects received NXN-188 and 35 received placebo. Most (91%) of the subjects were white; weight ranged from 69.3 to 71.8 kg (body mass index, 24.5–25.8 kg/m2 ). The initial absorption phase of orally administered NXN-188 peaked at ∼1 hour, followed by a second absorption phase with a Tmax of ∼4 to 5 hours. Exposure (Cmax and AUC) increased in a slightly greater than dose-proportional manner across a dose range of 2 to 800 mg (0.027–11.2 mg/kg). Elimination was multiexponential, with an initial rapid plasma drug elimination (plasma concentrations decreased ∼70%–90% from Cmax within 24 hours after dosing), followed by a prolonged clearance phase of very low NXN-188 concentrations (∼1%–5% of Cmax) that persisted for several weeks. Clearance ranged from 70 to 130 L/h, and the NXN-188 halflife ranged from 11 to 178 hours. Neither food nor gender had any measurable effect on the PK properties of NXN-188. Overall, dizziness was reported more often in the NXN-188 groups than in the placebo groups (6.3% vs 2.9%, respectively). Frequently reported adverse events that occurred more often in the placebo groups than in the NXN-188 groups were somnolence (11.4% vs 6.3%, respectively), and headache (8.6% vs 6.9%). Incidences of orthostatic hypotension (6.3% vs 5.7%) and postural (orthostatic) tachycardia syndrome (6.3% vs 5.7%) were comparable in the NXN-188 and placebo groups, respectively. No serious adverse events were reported at any dose of NXN-188 up to the current maximum dose (800 mg or 11.2 mg/kg). Conclusion : NXN-188 exhibited linear pharmaco-kinetics over the dose range studied and appeared to be well tolerated in these healthy volunteers.